Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

ASCO 2017: Routine Genomic Testing Is Viable for Subset of Patients

By Ryan Bushey | June 6, 2017

Results from a study of 1,944 patients with advanced cancer in France indicates widespread standard genomic testing is feasible for this group of patients.

This analysis, which was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, entailed using next-generation sequencing and whole-genome-comparative genomic hybridization to construct genomic profiles of tumors to help guide treatment decisions. Both technologies are widely available in France and elsewhere in the world, according to the authors.

The samples came from a variety of tumors including those of colorectal, gynecologic, breast, brain, headand neck cancer, and sarcoma patients. The technology analyzed 69 cancer-related genes.

An estimated 52 percent of these tumor samples contained actionable mutations, with 609 patients possessing one actionable mutation and 394 possessing two or more. The most common actionable mutation was the PI3K/mTOR pathway.

A multidisciplinary board of experts convened on a weekly basis to go over these genomic testing results and provide recommendations for the best targeted therapies.

“We recommended molecularly targeted therapies to patients who had mutations in pathways that could be targeted with either commercially available drugs or those tested in early clinical trials,” said lead study author Olivier Tredan, M.D., Ph.D., the chair of the Department of Medical Oncology at the Centre Léon Bérard in Lyon, France, in a statement.

Molecularly targeted treatments were recommended to 676 patients or 35 percent of the 1,944 tested according to availability of drugs hitting either the specific target protein or pathway activated by the target.

Of those 143 patients received the recommended treatments, mostly through clinical trial enrollment, while another 533 patients were ineligible to receive these drugs due to factors like poor health/rapid progression of cancer or not meeting the eligibility criterion for the clinical trials.

Ultimately, the scientists compared survival rates between the 143 patients who got these therapies against the 502 who did not.

About 53.7 percent of patients who got the recommended therapy targeted therapy were alive at three years versus 46.1 percent of patients who did not.

“This study confirms that comprehensive genomic profiling can be performed in routine practice to select patients for targeted cancer therapies,” continued Tredan. The technology is widely available and requires only a small amount of DNA. Theoretically, we could do this testing for every patient in France.”

The trial is still ongoing, but the team is planning a new phase of it the investigation where they will gage the 70-gene test used in this study to a commercial 315-gene test. The hope is that this would help ascertain if screening a large number of genes can lead to more targeted therapy recommendations.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

New cell imaging method reveals hidden enzyme activity 
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE